TSXV - Delayed Quote CAD

Marvel Biosciences Corp. (MRVL.V)

0.1200 0.0000 (0.00%)

At close: November 2 at 10:25:38 AM EST

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

GlobeNewswire 14d ago

MRVL.V
0.00%
MRVL

MBCOF
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model

GlobeNewswire 25d ago

MRVL.V
0.00%
MRVL

MBCOF
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update

GlobeNewswire 27d ago

MRVL.V
0.00%
MRVL

MBCOF
Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million

TMX Newsfile 1mo ago

MRVL.V
0.00%
MRVL
Marvel Biosciences Announces Extension to Closing Date of Private Placement

TMX Newsfile 1mo ago

MRVL.V
0.00%
MRVL
Marvel Biosciences Announces Grant of Deferred Share Units

TMX Newsfile 2mo ago
Marvel Biosciences Expands Private Placement to Quebec

TMX Newsfile 2mo ago

MRVL.V
0.00%
MRVL
Marvel Biosciences Announces Private Placement for up to $3.0 Million

TMX Newsfile 3mo ago

MRVL.V
0.00%
MRVL

MRVL.NE
Marvel Biosciences Announces Grant of Deferred Share Units

TMX Newsfile 5mo ago

MRVL.V
0.00%
MRVL

MRVL.NE
Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit

GlobeNewswire 6mo ago

MRVL.V
0.00%
MRVL

MRVL.NE
Marvel Biosciences Announces Closing of Convertible Debenture Offering

TMX Newsfile 6mo ago

MRVL.V
0.00%
MRVL

MRVL.NE
Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders

GlobeNewswire 6mo ago

MRVL.V
0.00%
MRVL

MBCOF

U.S. markets open in 7h 44m

Marvel Biosciences Corp. (MRVL.V)

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model

Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update

Marvel Biosciences Announces Closing of Private Placement For Up To $3.0 Million

Marvel Biosciences Announces Extension to Closing Date of Private Placement

Marvel Biosciences Announces Grant of Deferred Share Units

Marvel Biosciences Expands Private Placement to Quebec

Marvel Biosciences Announces Private Placement for up to $3.0 Million

Marvel Biosciences Announces Grant of Deferred Share Units

Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit

Marvel Biosciences Announces Closing of Convertible Debenture Offering

Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders